Assistant Director of Assessment and Accreditation

first_imgJob DescriptionThe Virginia Tech School of Education is inviting applications forthe position of Assistant Director of Assessment and Accreditation.The new Assistant Director will have the opportunity to buildassessment practices that ensure the continuous improvement ofcurricular programs in the School of Education. Additionally, theAssistant Director will help continue the School’s long-standing,successful record of attaining accreditation from the Council forthe Accreditation of Educator Preparation (CAEP), Council forAccreditation of Counselor and Related Educational Programs(CACREP), and Southern Association of Colleges and SchoolsCommission on Colleges (SACSCOC). This position is a calendar yearassistant or associate professor of practice appointment renewableevery five years.Responsibilities:The School of Education’s Assistant Director of Assessment andAccreditation is responsible for the design, implementation, andmanagement of a comprehensive and integrated assessment systemthat:• provides information to evaluate the productivity, effectiveness,and impact of the School’s academic programs, and• meets the accreditation requirements of multiple agencies.The Assistant Director is responsible for:1. Ongoing design and implementation of a digital quality assurancesystem that will provide valid and reliable data foradministrators, faculty, and staff to evaluate the School’sprograms2. Co-developing and overseeing the implementation of keyassessments, learning outcomes, and program outcomes that overlapwith meeting accreditation requirements (e.g. explore integrationof course management system for data collection)3. Working with faculty members, administrators, and otherstakeholders to implement assessment and evaluation activities forthe School of Education4. Collaborating with the University Office of Analytics andInstitutional Effectiveness to share already existing data andadvance the School of Education’s continuous improvementinitiatives5. Serving as liaison (or co-liaison) to CAEP and CACREP6. Managing unit accreditation reporting and visits, including allaspects of national and state accreditation reporting, writing unitand program level self-study reports (with input), and any relatedfollow-up reports, including annual updates7. Maintaining and strengthening a culture of assessment byroutinely reviewing assessments and reports to determine necessaryadjustments to existing curricula, ongoing assessment, datasources, and/or activities8. Representing VT SOE programs at relevant accreditationconferences and meetings, and communicating accreditation statusand progress to internal and external stakeholders9. Providing training to those involved in accreditationactivities, including the development and evaluation of keyassessments, data collection, analysis, and interpretation ofassessment data10. Possible teaching of educational research and evaluationcoursesRequired Qualifications• Terminal degree (Ph.D. or Ed.D.) from a regionally accreditedcollege or university in an appropriate discipline/field (e.g.,educational research, educational psychology, higher educationadministration, statistics) at the time of appointment• Knowledge of measurement, data analysis, research design, andqualitative and quantitative research methodologies• Demonstrated expertise of the principles and practices ofassessment and evaluation• Knowledge of regional and/or disciplinary accreditation standardsand reporting• Record of handling complex tasks, strong interpersonal,leadership, and communication skills• Demonstrated commitment to diversity and equity• Excellent written, verbal, and interpersonal communicationskillsPreferred Qualifications• Experience working with accreditation agencies• Working knowledge of SPSS, R, or comparable statistical analysisprogram• Teaching experience in higher education, online and/orface-to-face• Ability to develop, implement, and utilize informationsystems• Demonstrated project management skills• Awareness of obstacles and opportunities associated withfostering an institution-wide culture and commitment toassessment• Experience with or knowledge of grant evaluation practices• Experience in outcomes assessment and related activities within ahigher education setting• Advanced psychometric training and/or research experienceAppointment TypeRestrictedSalary InformationCommensurate with experienceReview DateReview of applications will begin on April 19, 2021, and continueuntil position is filled.Additional InformationTo apply, please submit (1) a cover letter detailing yourqualifications for the position and vision for the role ofAssistant Director of Assessment and Accreditation, (2) acurriculum vitae, and (3) names and contact information for threereferences. Application materials must be submitted online , Job number515594.The successful Candidate will be required to have a criminalconviction check.Employment is contingent upon submission of official universitytranscripts and a criminal background check.Occasional travel to national conferences is required.Questions may be directed to Bonnie Billingsley, Search CommitteeChair, at [email protected] Virginia TechDedicated to its motto, Ut Prosim (That I May Serve),Virginia Tech pushes the boundaries of knowledge by taking ahands-on, transdisciplinary approach to preparing scholars to beleaders and problem-solvers. A comprehensive land-grant institutionthat enhances the quality of life in Virginia and throughout theworld, Virginia Tech is an inclusive community dedicatedto knowledge, discovery, and creativity. The university offers morethan 280 majors to a diverse enrollment of more than 36,000undergraduate, graduate, and professional students in eightundergraduatecolleges , a school ofmedicine , a veterinarymedicine college, Graduate School , and Honors College . The universityhas a significant presence across Virginia, including the Innovation Campusin Northern Virginia; the Health Sciences and Technology Campus inRoanoke; sites in Newport News and Richmond; and numerous Extension offices andresearchcenters . A leading global research institution, Virginia Techconducts more than $500 million in research annually.Virginia Tech does not discriminate against employees, students, orapplicants on the basis of age, color, disability, sex (includingpregnancy), gender, gender identity, gender expression, geneticinformation, national origin, political affiliation, race,religion, sexual orientation, or veteran status, or otherwisediscriminate against employees or applicants who inquire about,discuss, or disclose their compensation or the compensation ofother employees or applicants, or on any other basis protected bylaw.If you are an individual with a disability and desire anaccommodation, please contact Sherri Albert at [email protected] regular business hours at least 10 business days prior tothe event.Advertised: March 30, 2021Applications close:last_img read more

Researchers develop new approach to assess effectiveness of Men B vaccine

first_img Source: Jun 18 2018Researchers at the University of Leicester and Meningococcal Reference Unit have developed a new approach to assess the effectiveness of the Men B vaccine, Bexsero®, against different strains that cause meningococcal meningitis and septicemia.The new approach allows direct testing of blood samples from patients with meningococcal disease to find out if the strain they are infected with might have been prevented by the vaccine. Currently, it is estimated that the vaccine offers protection against 73-88% of strains responsible for meningococcal disease in England and Wales.The approach is being assessed by Public Health England for its potential to routinely test all meningococcal disease cases.The research was based on looking at one of the four antigens that make up the vaccine. More work is needed to look at the remaining three antigens.Dr Chris Bayliss, from the University of Leicester’s Department of Genetics and Genome Biology, said: “This new research fills a gap in current testing capabilities that determine whether a disease-causing meningococcal strain is expected to be covered by the vaccine.”We are currently unable to obtain and grow live bacteria from up to half of patients to determine whether the vaccine might have prevented the type of meningococcal disease they have, often because treatment with antibiotics has already killed them. There is a need for new tests to identify and measure the amount of antigen by obtaining meningococcal DNA directly from patient samples.”Bexsero® is a vaccine that helps protect against group B meningococcal disease (MenB), developed by GSK. It was introduced into the UK infant immunization schedule in September 2015 and has been shown to be highly effective in preventing MenB disease in vaccinated infants.One of the protective components of Bexsero® is an antigen called factor H binding protein (fHbp). Infants vaccinated with MenB vaccines produce antibodies against this protein, so that if they are exposed to meningococcal bacteria that possess this protein, these antibodies will kill the bacteria.In a study published in the academic journal PLOS ONE, funded by Meningitis Research Foundation (MRF), the researchers show how a combination of DNA sequences and statistical testing can be used to measure the amounts of fHbp present in disease-causing meningococcal bacteria.Researchers and Mathematicians at the University of Leicester studied more than 2,000 disease-causing meningococcal isolates to measure how much antigen each strain produces.They used their results to categorize each strain into three classes: ‘covered’; ‘not covered’; and ‘at risk’. The ‘not covered’ groups included the ~12% of strains that will not be covered by the vaccine while the ‘at risk’ groups contains strains that are more likely to cause illness in vaccinated individuals.Related StoriesComputer-generated flu vaccine enters clinical trials in the USSchwann cells capable of generating protective myelin over nerves finds researchNanotechnology-based compound used to deliver hepatitis B vaccineDr Bayliss said: “Detailed molecular analyses of clinical samples are essential for understanding how efficient the new vaccines against meningococcal disease are at protecting people against different meningococcal strains.”This novel approach has the potential to help measure the effectiveness of Bexsero® more accurately.”The detailed information collected on the fHbp protein could be important in helping to improve the next generation of MenB vaccines.”Linda Glennie, Director of Research at MRF, said: “Introducing the MenB vaccine into the UK immunization schedule in 2015 was a major step forward. Vaccines are the only way to prevent bacterial meningitis and septicemia. The MenB vaccine has already been proven to be safe and effective and rates of MenB have been reducing since the introduction of the vaccine. Now that we have a vaccine in the schedule that gives good protection against MenB, these new testing techniques that the scientists have developed will give us crucial insights. Over the years, the strains that circulate in the UK have changed, and it is important to be certain about how much coverage the current MenB vaccines can provide, both now and in the future.””We are very encouraged by the results of the study , though measuring the attribution of only one antigen, fHbp, alone, without taking the effect of the other three components of Bexsero into consideration, may underestimate its protective effect,” said Rafik Bekkat-Berkani,MD. Global Medical Affairs Lead from GSK. “Bexsero’s 4 distinct components target different mechanisms in MenB survival and disease development and offer the potential to protect against invasive MenB strains even when the expression of one component is low or antigenically different. We agree with the study’s authors that more research is needed on Bexsero’s additional three antigens potentially providing multiple targets for vaccine-induced antibodies.”Shamez Ladhani, Paediatric Infectious Disease Consultant, Public Health England, said: “Since the introduction of the MenB vaccine program in 2015, cases of Meningococcal B disease have nearly halved in infants under 1 year and in one and two year olds, who became eligible for the 12-month booster in May 2016. However, any case of meningococcal disease is tragic and, unfortunately, not all cases of meningitis and septicemia are preventable through vaccines. This research is important in helping us understand how we can best protect those who are most at risk from a very serious disease.”last_img read more